Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: biologic sample preservation procedure, cytology specimen collection procedure.
- Who it may be relevant to
- Registry conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Lymphoproliferative Disorder. Basic parameters: 18 years — 120 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
Tissue Procurement For Hematolymphoid Conditions
Overview
RATIONALE: Collecting and storing samples of tissue, blood, and body fluid from patients with cancer to study in the laboratory may help the study of cancer in the future. PURPOSE: This research study is collecting and storing blood and tissue samples from patients being evaluated for hematologic cancer.
Detailed description
OBJECTIVES:
* Provide source of patient tissue, blood, and body fluid samples for ongoing diagnostic, prognostic, or immune-monitoring studies. * Support and enhance translational, clinical and basic research for Lineberger Comprehensive Cancer Center (LCCC) members (and non-members who have an LCCC member as sponsor and collaborator) with IRB-approved studies. * Maintain responsible and appropriate policies and procedures that ensure good patient care and responsible conduct of research. * Address medical and legal issues, and protect participant and patient privacy and confidentiality. * Provide a responsible and uniform mechanism for the integrated coordination of the hemato-pathologist and surgeon or hematology/oncology staff, researcher, and protocol office to obtain appropriate specimens for researchers. * Support young investigators to obtain pilot data for grant funding.
OUTLINE: Patients undergo tissue, blood, and body fluid collection during diagnostic or routine procedures for future correlative studies. Tissue samples may include, but are not limited to, lymph node or non-nodal biopsies, bone marrow biopsy and/or aspirate, blood and serum, and buccal swabs for germline DNA analysis.
Interventions
- Other biologic sample preservation procedure
All samples collected during routine clinical care. - Other cytology specimen collection procedure
All Samples collected during routine clinical care.
Primary outcome measures
- Tissue, blood, and body fluid samples collection for ongoing diagnostic, prognostic, or immune-monitoring studies [Time frame: 30 years]
- Development of a centralized, quality-controlled, quality-assured facility for the procurement, processing, storage, and distribution of normal and malignant tissue specimens and corresponding blood specimens [Time frame: 30 years]
Eligibility criteria
DISEASE CHARACTERISTICS:
- Diagnosis of abnormal hematopoietic/lymphoid cancer, including any of the following:
- Acute myeloid leukemia
- Acute lymphoblastic leukemia
- Chronic myelogenous leukemia
- Chronic lymphoid leukemia
- Non-Hodgkin lymphoma
- Hodgkin lymphoma
- Myelodysplastic syndromes
- Myeloproliferative disorders
- Multiple myeloma
- Waldenstrom macroglobulinemia
- Aplastic anemia
- Any other diseases that generate abnormalities in either number, function, or both of any cell type of hematolymphoid lineage
- Patients who are being evaluated at the hematology/oncology clinics of the University of North Carolina Hospitals, at the stem cell transplant clinic, or in the hospital
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- Not specified
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Observational model
- Other
Study locations
United States · 1 center
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill — Chapel Hill
Identifiers
NCT: NCT01137643 · LCCC 0824 · P30CA016086 · CDR0000674072